Aehr Test Systems

AEHR remains in a constructive uptrend, confirmed by higher highs and higher lows, and supported by rising EMAs and healthy options sentiment. Price is extended above the 9/20/50 EMAs without a clear pullback entry, warranting patient stalking for a consolidation or retracement into the EMA support zone before engaging.

• ↑$22M follow-on order aligns AI revenue mix to over 90% of sales
• ↑Record Q4 bookings of $60.7M and $100.6M backlog drive FY27 visibility
• ↓Shares up >500% YTD vs 43% YoY revenue decline highlights stretched valuation